The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.

① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.

cls.cnFeb 28 10:46 ET

[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.

Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).

King Wu Financial NewsFeb 10 01:45 ET

Zhaoyin International: Bullish on the valuation repair of the China Meheco Group Industry, recommending to Buy WUXI APPTEC (02359) and others.

Cinda International believes that China will become a necessary place for overseas pharmaceutical companies to seek innovative drug pipelines, and innovative drugs from China will play an increasingly important role on the international stage.

Zhitong FinanceFeb 9 20:46 ET

China Meheco Group (SHSE:600056) Shareholders Notch a 14% CAGR Over 3 Years, yet Earnings Have Been Shrinking

Simply Wall StFeb 7 21:24 ET

Announcement on the pre-reduction of 2024 results

SZSIJan 24 11:00 ET · Announcements

China Meheco Group (600056.SH): The net income for the year 2024 is expected to decrease by 68% to 45%.

Glory Network reported on January 24 that China Meheco Group (600056.SH) announced a reduction in the 2024 annual performance forecast. According to preliminary calculations by the financial department, it is expected that the net income attributable to shareholders of the listed company will be between 0.335 billion yuan and 0.576 billion yuan, representing a year-on-year decrease of 68% to 45%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 0.231 billion yuan and 0.472 billion yuan, which is a year-on-year decrease of 62% to 23%. This reduction in performance is primarily due to the impacts of domestic centralized procurement price reductions, increased market competition, and tightening international demand.

Gelonghui FinanceJan 24 08:03 ET